Inhibition of mitotic kinase Aurora suppresses Akt-1 activation and induces apoptotic cell death in all-trans retinoid acid-resistant acute promyelocytic leukemia cells

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Xu, Duo Rong ^a,b   Huang, Shan ^a,b   Long, Zi Jie ^b   Chen, Jia Jie ^b   Zou, Zheng Zhi ^a   Li, Juan ^b   Lin, Dong Jun ^b   Liu, Quentin ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AURORA KINASE INHIBITOR; CASPASE; CD11B ANTIGEN; HOE 33342; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROCASPASE 3; PROTEIN KINASE B; RETINOIC ACID; THREONINE; TOZASERTIB; AURORA KINASE; PIPERAZINE DERIVATIVE; PROPIDIUM IODIDE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; ASSAY; AUTOPHOSPHORYLATION; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; DEPOLARIZATION; DRUG USE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REPRESSION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; LEUKEMIA CELL; MITOCHONDRION; MITOSIS SPINDLE; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOSIS; MOLECULAR LIBRARY; PATHOLOGY; TUMOR CELL LINE;

ANNEXIN A5; APOPTOSIS; CASPASES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOSIS; MITOTIC SPINDLE APPARATUS; PIPERAZINES; PROPIDIUM; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SMALL MOLECULE LIBRARIES; TRETINOIN;

EID: 79956214364     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-74     Document Type: Article

References (41)

1. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, Ogden A, Weinstein H, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002, 100:4298-302. 10.1182/blood-2002-02-0632, 12393590.
2. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008, 111:2505-15. 10.1182/blood-2007-07-102798, 18299451.
3. Chambon P. Adecade of molecular biology of retinoic acid receptors. FASEB J 1996, 10:940-54.
4. Lin RJ, Sternsdorf T, Tini M, Evans RM. Transcriptional regulation in acute promyelocytic leukemia. Oncogene 2001, 20:7204-15. 10.1038/sj.onc.1204853, 11704848.
5. Marumoto T, Zhang D, Saya H. Aurora-A: a guardian of poles. Nat Rev Cancer 2005, 5:42-50. 10.1038/nrc1526, 15630414.
6. Meraldi P, Honda R, Nigg EA. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev 2004, 14:29-36. 10.1016/j.gde.2003.11.006, 15108802.
7. Liu Q, Ruderman JV. Aurora A, mitotic entry, and spindle bipolarity. Proc Natl Acad Sci USA 2006, 103:5811-6. 10.1073/pnas.0601425103, 1421333, 16581905.
8. Macarulla T, Ramos FJ, Tabernero J. Aurora kinase family: a new target for anticancer drug. Recent Pat Anticancer Drug Discov 2008, 3:114-22. 10.2174/157489208784638785, 18537754.
9. Lee EC, Frolov A, Li R, Ayala G, Greenberg NM. Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res 2006, 66:4996-5002. 10.1158/0008-5472.CAN-05-2796, 16707419.
10. Li D, Zhu J, Firozi PF, Abbruzzese JL, Evans DB, Cleary K, Friess H, Sen S. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 2003, 9:991-7.
11. Kaestner P, Stolz A, Bastians H. Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol Cancer Ther 2009, 8:2046-56. 10.1158/1535-7163.MCT-09-0323, 19584233.
12. Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y. Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res 1999, 59:2041-4.
13. Ulisse S, Baldini E, Toller M, Delcros JG, Guého A, Curcio F, De Antoni E, Giacomelli L, Ambesi-Impiombato FS, Bocchini S, D'Armiento M, Arlot-Bonnemains Y. Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues. Ann Surg Oncol 2007, 14:719-29. 10.1245/s10434-006-9178-6, 17115102.
14. Mazumdar A, Henderson YC, El-Naggar AK, Sen S, Clayman GL. Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck 2009, 31:625-34. 10.1002/hed.21007, 2668723, 19107951.
15. Siu LL. Promising new targeted agents in head and neck cancer. Int J Radiat Oncol Biol Phys 2007, 69:59-60.
16. Huang XF, Luo SK, Xu J, Li J, Xu DR, Wang LH, Yan M, Wang XR, Wan XB, Zheng FM, Zeng YX, Liu Q. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis inAurora-A-high acute myeloid leukemia. Blood 2008, 111:2854-65. 10.1182/blood-2007-07-099325, 18160664.
17. Shi Y, Reiman T, Li W, Maxwell CA, Sen S, Pilarski L, Daniels TR, Penichet ML, Feldman R, Lichtenstein A. Targeting aurora kinases as therapy in multiple myeloma. Blood 2007, 109:3915-21. 10.1182/blood-2006-07-037671, 1874561, 17213289.
18. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007, 109:500-2. 10.1182/blood-2006-05-025049, 16990603.
19. Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007, 117:2562-9. 10.1172/JCI30890, 1940237, 17710227.
20. Crane R, Gadea B, Littlepage L, Wu H, Ruderman JV. Aurora A, meiosis and mitosis. Biol Cell 2004, 96:215-29. 10.1016/j.biolcel.2003.09.008, 15182704.
21. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Gandara DR. Aurora Kinases as Anticancer Drug Targets. Clin Cancer Res 2008, 14:1630-48.
22. Wan XB, Long ZJ, Yan M, Xu J, Xia LP, Liu L, Zhao Y, Huang XF, Wang XR, Zhu XF, Hong MH, Liu Q. Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells. Carcinogenesis 2008, 29:1930-7. 10.1093/carcin/bgn176, 18667445.
23. Pan C, Yan M, Yao J, Xu J, Long Z, Huang H, Liu Q. Aurora kinase small molecule inhibitordestroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells. Oral Oncology 2008, 44:639-45. 10.1016/j.oraloncology.2007.08.010, 17996488.
24. Guan Z, Wang XR, Zhu XF, Huang XF, Xu J, Wang LH, Wan XB, Long ZJ, Liu JN, Feng GK, Huang W, Zeng YX, Chen FJ, Liu Q. Aurora-A, a Negative Prognostic Marker, Increases Migration and Decreases Radiosensitivity in Cancer Cells. Cancer Res 2007, 67:10436-44. 10.1158/0008-5472.CAN-07-1379, 17974987.
25. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002, 99:759-67. 10.1182/blood.V99.3.759, 11806975.
26. Avvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, Lazzarino M, Russo D, Petti MC, Mandelli F. AIDA (alltrans retinoic acid+idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996, 88:1390-8.
27. Fenaux P, Wang ZZ, Degos L. Treatment of acute promyelocytic leukemia by retinoids. Curr Top Microbiol Immunol 2007, 313:101-28. 10.1007/978-3-540-34594-7_7, 17217041.
28. Takayama N, Kizaki M, Hida T, Kinjo K, Ikeda Y. Novel mutation in the PML/RARα chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia. Experimental Hematology 2001, 29:864-72. 10.1016/S0301-472X(01)00651-8, 11438209.
29. Shao W, Benedetti L, Lamph WW, Nervi C, Miller WH. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation. Blood 1997, 89:4282-9.
30. Witcher M, Shiu HY, Guo Q, Miller WH. Combination of retinoic acid and tumor necrosis factor overcomes the maturation block in a variety of retinoic acid-resistant acute promyelocytic leukemia cells. Blood 2004, 104:3335-42. 10.1182/blood-2004-01-0023, 15256426.
31. Duprez E, Benoit G, Flexor M, Lillehaug JR, Lanotte M. A mutated PML/RARA found in the retinoid maturation resistant NB4 subclone, NB4-R2, blocks RARA and wild-type PML/RARA transcriptional activities. Leukemia 2000, 14:255-61. 10.1038/sj.leu.2401683, 10673742.
32. Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR, et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 1995, 85:1083-94.
33. Raghu KH, Yadav GK, Singh R, Prathapan A, Sharma S, Bhadauria S. Evaluation of adverse cardiac effects induced by arsenic trioxide, a potent anti-APL drug. J Environ Pathol Toxicol Oncol 2009, 28:241-52.
34. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JM, Miller KM. VX-680, a potent and selective small-molecule inhibitor of the aurora kinases, suppresses tumor growth in vivo. Nat Med 2004, 10:262-7. 10.1038/nm1003, 14981513.
35. Glover DM, Leibowitz MH, McLean DA, Parry H. Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 1995, 81:95-105. 10.1016/0092-8674(95)90374-7, 7720077.
36. Briassouli P, Chan F, Savage K, Reis-Filho JS, Linardopoulos S. Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha. Cancer Res 2007, 67:1689-95. 10.1158/0008-5472.CAN-06-2272, 17308110.
37. Yao JE, Yan M, Guan Z, Pan CB, Xia LP, Li CX, Wang LH, Long ZJ, Zhao Y, Li MW, Zheng FM, Xu J, Lin DJ, Liu Q. Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival. Mol Cancer 2009, 8:95. 10.1186/1476-4598-8-95, 2780390, 19891769.
38. Brenner D, Mak TW. Mitochondrial cell death effectors. Curr Opin Cell Biol 2009, 21:871-7. 10.1016/j.ceb.2009.09.004, 19822411.
39. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-74. 10.1016/j.cell.2007.06.009, 2756685, 17604717.
40. Billottet C, Banerjee L, Vanhaesebroeck B, Khwaja A. Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation. Cancer Res 2009, 69:1027-36. 10.1158/0008-5472.CAN-08-2608, 19176369.
41. Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T, Paktinat M, Gilliland DG, Gritsman K. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood 2010, 115:1406-15. 10.1182/blood-2009-06-229443, 2826762, 20008787.